Drug
Tgr 1202
Tgr 1202: highest development phase Phase 2, developed by TG Therapeutics, United Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- TG Therapeutics, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| TGR-1202 NCT03178201 | Phase 2 | Follicular Lymphoma |
| TGR-1202 NCT03207256 | Phase 2 | Chronic Lymphocytic Leukemia |
| TGR-1202 NCT02268851 | Phase 1 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| TGR-1202 NCT01767766 | Phase 1 | Non-Hodgkin's Lymphoma |
Latest
No recent events.
Follow Tgr 1202 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.